Targeting Lipids to Improve Outcomes in Your Cath Patients-Statins and Non-statin Therapy: For Whom and When

Statins and Non-statin Therapy: For Whom and When

Video Transcription

Video Summary

The discussion focuses on the challenges in managing LDL levels, emphasizing the importance of routinely checking lipid profiles, especially for high-risk ASCVD patients, including minorities and underserved populations. Despite extensive evidence supporting the effectiveness of statins, many patients remain under-treated. The talk highlights various LDL-lowering therapies, such as PCSK9 inhibitors, Zetia, bimbidoic acid, and inclisiran, emphasizing their substantial cardiovascular benefits. It stresses the significance of adjunctive therapies for statin-intolerant patients and underscores the need for proactive management to reduce major cardiovascular events and improve long-term patient outcomes.

Asset Subtitle

Peter Monteleone, MD, FSCAI

Keywords

LDL management

ASCVD patients

LDL-lowering therapies

statin intolerance

cardiovascular outcomes